CLRB - セレクタ・バイオサイエンシ―ズ (Cellectar Biosciences Inc.)

CLRBのニュース

   Wiling stocks: Verb Technology Company, Inc. (NASDAQ:VERB 0.24%), Cellectar Biosciences, Inc. (NASDAQ:CLRB 3.12%)  2021/10/29 00:16:00 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Wiling stocks: Verb Technology Company, Inc. (NASDAQ:VERB 0.24%), Cellectar Biosciences, Inc. (NASDAQ:CLRB 3.12%) appeared first on Stocks Equity .
   Cellectar Biosciences (NASDAQ:CLRB) Downgraded by Zacks Investment Research to Hold  2021/10/13 16:29:00 Stock Market Daily
Cellectar Biosciences} stock has undergone multiple analysts rating changes in the recent past. Cellectar Biosciences Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy. The post Cellectar Biosciences (NASDAQ:CLRB) Downgraded by Zacks Investment Research to Hold appeared first on .
   Astonishing stocks: Cameco Corporation (NYSE:CCJ 7.66%), Cellectar Biosciences, Inc. (NASDAQ:CLRB 3.73%)  2021/10/12 22:44:44 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Astonishing stocks: Cameco Corporation (NYSE:CCJ 7.66%), Cellectar Biosciences, Inc. (NASDAQ:CLRB 3.73%) appeared first on Stocks Equity .
   Wiggling stocks: Golden Minerals Company (AMEX:AUMN 0.84%), Cellectar Biosciences, Inc. (NASDAQ:CLRB -0.30%)  2021/10/08 04:23:36 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Wiggling stocks: Golden Minerals Company (AMEX:AUMN 0.84%), Cellectar Biosciences, Inc. (NASDAQ:CLRB -0.30%) appeared first on Stocks Equity .
   Cellectar Biosciences (CLRB) Investor Presentation - Slideshow  2021/09/24 23:04:57 Seeking Alpha
   Wiggling stocks: Golden Minerals Company (AMEX:AUMN 0.84%), Cellectar Biosciences, Inc. (NASDAQ:CLRB -0.30%)  2021/10/08 04:23:36 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Wiggling stocks: Golden Minerals Company (AMEX:AUMN 0.84%), Cellectar Biosciences, Inc. (NASDAQ:CLRB -0.30%) appeared first on Stocks Equity .
   Cellectar Biosciences (CLRB) Investor Presentation - Slideshow  2021/09/24 23:04:57 Seeking Alpha
   Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer  2021/09/22 12:30:00 Benzinga
FLORHAM PARK, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB ), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the completion of the part A portion of a safety and tolerability study of iopofosine I-131 (iopofosine) in combination with external beam radiation (EBRT) in relapsed or refractory head and neck cancer. This Investigator initiated study is being conducted by the University of Wisconsin as part of a prestigious Specialized Program of Research Excellence (SPORE) grant awarded by the National Cancer Institute. The University of Wisconsin clinical trial under direction of principal investigator, Dr. Justine Yang Bruce is evaluating the potential for iopofosine in combination with EBRT to reduce the total dose (Grays) and number of fractions of external beam radiation while maintaining favorable tumor response rates. The reduction in the amount or fractions (doses) of EBRT has the potential to diminish the (number and severity of) adverse events associated with EBRT.
   Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit  2021/09/15 20:01:00 Intrado Digital Media
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that James Caruso, president and CEO, will present a company overview at the following upcoming conference:
   Cellectar Receives $2M NIH Grant For Rare Lymphoma Study  2021/08/18 15:54:58 Benzinga
Cellectar Biosciences Inc (NASDAQ: CLRB ) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal study of iopofosine I-131 Full story available on Benzinga.com
   Cellectar Receives $2M NIH Grant For Rare Lymphoma Study  2021/08/18 15:54:58 Benzinga
Cellectar Biosciences Inc (NASDAQ: CLRB ) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from the National Cancer Institute (NCI). The Company is currently conducting a pivotal study of iopofosine I-131 Full story available on Benzinga.com
   Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom''s Macroglobulinemia  2021/08/18 12:30:00 Benzinga
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB ), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI). The company is currently conducting a global pivotal study of iopofosine I-131 (also known as CLR 131) in Waldenstrom''s macroglobulinemia (WM) patients who have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitor failed or suboptimal response patients. The study was initiated in January of 2021 and is expected to take approximately 18 months to fully enroll. "We appreciate the recognition and funding that the NIH and NCI have chosen to provide Cellectar for our pivotal iopofosine program. WM is an incurable disease with existing treatment options restricted to one approved drug and various unapproved salvage therapies," said James Caruso, president and CEO of Cellectar. "This $2 million non-dilutive grant will be used to support and accelerate the ongoing pivotal study.
   Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstroms Macroglobulinemia  2021/08/18 12:30:00 Intrado Digital Media
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced it has been awarded a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 Million from the National Cancer Institute (NCI).
   Impulsive Stock: Bit Digital, Inc. (NASDAQ:BTBT), Cellectar Biosciences, Inc. (NASDAQ:CLRB)  2021/08/17 21:19:21 Stock Equity
Bit Digital, Inc. (NASDAQ:BTBT) with the stream of -5.49% also noticed, India Cellectar Biosciences, Inc. (NASDAQ:CLRB) encountered a rapid change of -2.22% in the last hour of Tuesdays trading session. The post Impulsive Stock: Bit Digital, Inc. (NASDAQ:BTBT), Cellectar Biosciences, Inc. (NASDAQ:CLRB) appeared first on Stocks Equity .
   Stock on fire: Cellectar Biosciences, Inc. (NASDAQ:CLRB), Qumu Corporation (NASDAQ:QUMU)  2021/08/17 01:12:59 Stock Equity
Cellectar Biosciences, Inc. (CLRB) with the stream of 4.94% also noticed, India Qumu Corporation (QUMU) encountered a rapid change of 10.80% in the last hour of Mondays trading session. Cellectar The post Stock on fire: Cellectar Biosciences, Inc. (NASDAQ:CLRB), Qumu Corporation (NASDAQ:QUMU) appeared first on Stocks Equity .

calendar